Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases, with its lead candidate molgramostim (inhaled GM-CSF) targeting autoimmune pulmonary alveolar proteinosis (aPAP). The company has no commercial revenue and operates as a pure R&D entity dependent on clinical trial outcomes and regulatory approvals. Stock performance is driven entirely by clinical data readouts, FDA interactions, and partnership/financing announcements rather than traditional operational metrics.
Savara operates a classic biotech development model: raise capital through equity offerings and debt, fund clinical trials to demonstrate safety/efficacy, obtain regulatory approval, then commercialize directly or through partners. The aPAP indication represents an orphan disease market with approximately 1,000-2,000 diagnosed patients in the US, allowing premium pricing ($200K-$400K annually estimated) with limited competition. Success depends entirely on Phase 3 IMPALA-2 trial results and subsequent FDA approval. The company has no manufacturing infrastructure and will likely outsource production, maintaining an asset-light model focused on clinical development and commercialization strategy.
IMPALA-2 Phase 3 trial data readouts and interim analyses for molgramostim in aPAP patients
FDA regulatory interactions including Advisory Committee meetings, Complete Response Letters, or approval decisions
Capital raises and cash runway announcements (dilution concerns vs. funding security trade-off)
Strategic partnership announcements for ex-US commercialization rights or alternative indications
Competitive developments in aPAP treatment landscape or alternative GM-CSF therapies
Binary clinical trial risk: IMPALA-2 failure would eliminate primary value driver with limited pipeline depth to offset
Orphan disease market size constraints: Even with approval, aPAP patient population of 1,000-2,000 in US limits peak revenue potential to $200M-$400M annually
Regulatory pathway uncertainty: FDA may require additional studies or impose restrictive labeling that limits commercial opportunity
Reimbursement risk: Payers may challenge premium pricing despite orphan status, particularly if clinical benefit vs. standard whole lung lavage is deemed incremental
Alternative aPAP therapies in development including gene therapies or next-generation GM-CSF formulations with superior delivery mechanisms
Academic medical centers may resist adoption if whole lung lavage procedures generate significant institutional revenue
Biosimilar or generic competition post-exclusivity period (2034+) would erode pricing power despite specialized delivery requirements
Cash burn of approximately $100M annually with zero revenue creates continuous dilution risk and potential down-rounds if trial data disappoints
Current ratio of 7.65x appears strong but absolute cash position likely supports only 12-18 months of operations without additional financing
Debt/equity of 0.32 suggests convertible notes or term loans that may trigger dilutive conversions or require refinancing at unfavorable terms
Negative ROE of -86.6% and ROA of -89.5% reflect accumulated deficit and will persist until commercialization
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact ability to raise capital at favorable terms and may delay commercialization infrastructure investments. Rare disease treatment demand is non-discretionary and unaffected by economic cycles once approved.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (approval potentially 2027-2028, peak sales 2030+). Higher rates also increase cost of debt financing and make equity raises more dilutive as biotech valuations compress. The company's 7.65x current ratio provides liquidity buffer, but eventual refinancing of the 0.32 debt/equity position becomes more expensive in high-rate environments. Rate cuts would support multiple expansion for pre-revenue growth assets.
Moderate - While operations are not credit-dependent, access to capital markets is critical for survival. Credit spread widening reduces institutional appetite for speculative biotech debt and forces greater reliance on dilutive equity. Investment-grade credit conditions indirectly affect biotech sector sentiment and M&A activity (potential acquirers' financing costs).
growth/speculative - Attracts biotech-specialized funds, event-driven hedge funds positioning for binary clinical catalysts, and retail investors seeking high-risk/high-reward asymmetric payoffs. The 99.3% one-year return and 86.2% six-month return indicate momentum-driven trading around clinical milestones. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend potential. Institutional ownership likely concentrated among healthcare-focused funds with expertise evaluating clinical trial data and regulatory pathways.
high - Clinical-stage biotechs exhibit extreme volatility with 30-50% single-day moves common around data releases. Beta likely exceeds 2.0x relative to broader market. The recent 36.2% three-month gain suggests positive sentiment into upcoming catalysts, but downside risk is proportional. Options market typically prices 80-100% implied volatility around known data events. Liquidity can evaporate quickly on negative news given $1.2B market cap and speculative investor base.
